Related Experiment Video
Updated: Apr 26, 2026
09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.1K
TYROBP in Alzheimer's disease
1Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao, Shandong, China.
Molecular Neurobiology
|July 24, 2014
Summary
TYRO protein tyrosine kinase-binding protein (TYROBP) is upregulated in Alzheimer's disease (AD) brains. TYROBP may protect against AD by enhancing microglial clearance of toxic proteins and suppressing inflammation.
Area of Science:
- Neuroimmunology
- Molecular Biology
- Alzheimer's Disease Research
Background:
- TYRO protein tyrosine kinase-binding protein (TYROBP) is a key immune regulator.
- TYROBP is significantly upregulated in Alzheimer's disease (AD) brain tissue.
- TYROBP functions as a signaling adaptor for various cell surface receptors involved in immune responses.
Purpose of the Study:
- To review the structure, localization, and function of TYROBP.
- To examine the association of TYROBP and its related receptors with AD pathogenesis.
- To speculate on the potential roles of TYROBP in AD and its therapeutic implications.
Main Methods:
- Literature review of recent articles on TYROBP and AD.
- Analysis of TYROBP's role in microglial phagocytosis and inflammatory signaling.
- Exploration of TYROBP's interaction with TREM2, SIRPβ1, and CR3 in AD.
Main Results:
- TYROBP enhances microglial phagocytic activity, aiding clearance of amyloid-β (Aβ) peptides and apoptotic neurons.
- TYROBP suppresses inflammatory responses by reducing microglia-mediated cytokine production.
- TYROBP and its receptors (TREM2, SIRPβ1, CR3) are implicated in AD pathogenesis.
Conclusions:
- TYROBP exhibits potential protective functions in Alzheimer's disease.
- Targeting TYROBP may offer novel therapeutic strategies for AD treatment.
- Further research is needed to fully elucidate TYROBP's complex role in AD pathogenesis.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
27
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
27
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:29Alzheimer Disease l: Introduction
19
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
19
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:00Enzyme-linked Receptors
64.5K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
64.5K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81